Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan

被引:14
|
作者
Hsu, Ching-Sheng
Liu, Chun-Jen
Lai, Ming-Yang
Chen, Pei-Jer
Kao, Jia-Horng
Chen, Ding-Shinn
机构
[1] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei 100, Taiwan
[2] Buddhist Tzu Chi Gen Hosp, Dept Hepatogastroenterol, Dept Internal Med, Taipei Branch, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Med, Dept Med Res, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Taipei 10764, Taiwan
[6] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
关键词
hepatitis C virus; viral kinetics; pegylated interferon; interferon; ribavirin;
D O I
10.1159/000105444
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objectives: Early hepatitis C viral ( HCV) kinetics following pegylated interferon-alpha (PEG-IFN) and ribavirin help to assess treatment in the Western world. Whether this functions in Taiwanese patients remains unknown. Studying the early HCV kinetics in Taiwanese patients may clarify this issue. Methods: Six chronic hepatitis C patients were enrolled. A PEG-IFN-alpha dose was administered at week 1, then it was administered weekly with daily ribavirin for 24 weeks. Serum HCV RNA levels were determined frequently during the trial and qualitatively at week 49. Kinetic parameters epsilon ( effectiveness at inhibiting viral production) and delta ( loss rate of infected cells) were estimated from viral loads and alanine aminotransferase ( ALT) kinetics, respectively. Results: All serum HCV RNA levels became undetectable at week 12. The epsilon ranged from 0.4128 to 0.9904 and delta from 0.0019 to 0.1245. The log values of viral load differences between day 7 and 14 ranged from 0.15 to 1.21. Only 1 patient had an abnormal ALT level at week 49. Conclusions: Viral kinetic parameters in Taiwanese patients were similar to those in Western studies. However, the early viral decline pattern and viral negativity rate in Taiwanese patients might be different from Caucasian patients. Further large-scale studies to clarify this issue are ongoing. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [1] Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus
    Foster, GR
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (05) : 685 - 691
  • [2] Pegylated interferon and ribavirin treatment for hepatitis C virus infection
    Palumbo, Emilio
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2011, 2 (01) : 39 - 45
  • [3] Retinopathy with pegylated interferon alpha 2a and ribavirin during a chronic viral hepatitis C
    Ngatcha, G.
    Rouibaa, F.
    Majdouli, S.
    Arouah, A.
    Feqhi, A.
    Oubaaz, A.
    JOURNAL AFRICAIN D HEPATO-GASTROENTEROLOGIE, 2013, 7 (01): : 53 - 56
  • [4] Early viral kinetics on treatment with pegylated interferon-α-2a in chronic hepatitis C virus genotype 1 infection
    Jessner, W
    Stauber, R
    Hackl, F
    Datz, C
    Watkins-Riedel, T
    Hofer, H
    Gangl, A
    Kessler, H
    Ferenci, P
    JOURNAL OF VIRAL HEPATITIS, 2003, 10 (01) : 37 - 42
  • [5] Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection
    Chen, Li-Wei
    Chien, Rong-Nan
    Yen, Cho-Li
    Chang, Jia-Jang
    Liu, Ching-Jung
    Lin, Chih-Lang
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (02) : 259 - 263
  • [6] Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C
    Seyam, MS
    Freshwater, DA
    O'Donnell, K
    Mutimer, DJ
    JOURNAL OF VIRAL HEPATITIS, 2005, 12 (05) : 531 - 535
  • [7] Pegylated interferon plus ribavirin in chronic hepatitis c
    Bruce R. Bacon
    Current Gastroenterology Reports, 2001, 3 (1) : 84 - 84
  • [8] Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
    Kanda, T.
    Yokosuka, O.
    JOURNAL OF NEPAL MEDICAL ASSOCIATION, 2011, 50 (01) : 41 - 48
  • [9] Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C
    Brochot, Etienne
    Riachi, Ghassan
    Plantier, Jean-Christophe
    Guillemard, Catherine
    Vabret, Astrid
    Mathurin, Philippe
    Nguyen-Khac, Eric
    Duverlie, Gilles
    JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (07) : 1191 - 1198
  • [10] Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT
    Al-Ali, Jaber
    Siddique, Iqbal
    Varghese, Rosh
    Hasan, Fuad
    ANNALS OF HEPATOLOGY, 2012, 11 (02) : 186 - 193